My ePortfolio Register   

Extending indication of CDK 4/6 inhibitors in the adjuvant and neoadjuvant setting

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.10.16
Views: 1293

Dr Sara Hurvitz - UCLA Medical Center, Santa Monica, USA

Dr Hurvitz discusses preclinical data for palbociclib, ribociclib and abemaciclib in the 'Coming of Age CDK 4/6 Inhibition' symposium at the ESMO 2016 conference.

Supported by a grant from Pfizer Inc.

Related videos

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence